Cybin Inc., a clinical-stage biopharmaceutical company, has announced the expansion of its strategic partnership agreements to include 18 U.S. clinical sites for its multinational Phase 3 trial of CYB003. This next-generation psychedelic-based therapy targets major depressive disorder (MDD), marking a significant step forward in the development of innovative mental health treatments. The APPROACH study, part of Cybin’s PARADIGM program, is expected to expand to approximately 45 sites, leveraging site-specific expertise to enhance protocol consistency and accelerate trial timelines.
Notable partners in this expansion include CenExel iResearch Atlanta and Cedar Clinical Research, institutions recognized for their contributions to clinical research. This strategic move underscores Cybin’s commitment to revolutionizing mental healthcare through the development of safe and effective psychedelic-based therapeutics. The company’s efforts are supported by a network of world-class partners and internationally recognized scientists, focusing on proprietary drug discovery platforms and novel formulation approaches.
CYB003, a proprietary deuterated psilocybin analog, represents a promising avenue for treating MDD, a condition with a significant unmet need for new treatment options. The expansion of clinical trial sites is a critical milestone in Cybin’s mission to address this gap, offering potential benefits to patients worldwide. For more information on Cybin’s groundbreaking work, visit https://www.Cybin.com.
